Cargando…
Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma
Etomidate is a very effective drug in severe Cushing's syndrome that is refractory to ketoconazol. Control of the serum cortisol levels in ectopic Cushing's syndrome can be obtained with infusion rates much lower than those used in anesthesia, without respiratory side effects.
Autores principales: | Reza‐Albarrán, Alfredo Adolfo, Andino Ríos, Gerson Geovany, Gómez Herrera, Laura Gabriela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930188/ https://www.ncbi.nlm.nih.gov/pubmed/29744071 http://dx.doi.org/10.1002/ccr3.1478 |
Ejemplares similares
-
Pharmacological management of severe Cushing’s syndrome: the role of etomidate
por: Pence, Andrea, et al.
Publicado: (2022) -
Nonfunctioning Pituitary Adenoma That Changed to a Functional Gonadotropinoma
por: Andino-Ríos, Gerson Geovany, et al.
Publicado: (2018) -
Continuous Etomidate Infusion for the Management of Severe Cushing Syndrome: Validation of a Standard Protocol
por: Carroll, Ty B, et al.
Publicado: (2018) -
Cushing’s syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia
por: Dzialach, Lukasz, et al.
Publicado: (2022) -
Using Etomidate in a Two-month-old Infant with Cushing Syndrome due to Adrenocortical Carcinoma
por: Kwon, Ahreum, et al.
Publicado: (2022)